Pathos AI Raises $237 Million in Series E Financing

Pathos AI, an AI-driven drug development company, has secured $237 million in Series E financing at a post money valuation of approximately $3 billion.

The round was led by Bristol Myers Squibb, with participation from existing investors.

The company will use the funding to expand its proprietary AI platform, Foundry, and accelerate the clinical development of its drug pipeline. Its priorities include advancing cancer treatments, including a potential therapy targeting TROP2 and HER3, toward later-stage clinical studies.

What is Pathos AI?

Pathos AI is a technology company that uses artificial intelligence to develop drugs and guide clinical research. Rather than focusing only on drug discovery, the company applies AI throughout the development process, from selecting drug candidates to making decisions about clinical trials.

Read More:DentalXChange Appoints Scott Hampel as President

Its proprietary platform, Foundry, uses thousands of specialised AI agents to analyse information related to drug development. This includes clinical data, genomics, biological specimen data, and changes in the competitive landscape.

The platform helps Pathos identify patient groups that may respond to particular treatments, assess clinical trial results, and identify potential risks earlier in development.

How Much Funding Has Pathos AI Raised?

Pathos AI has raised $237 million in its Series E financing round. The investment values the company at approximately $3 billion after the funding.

Who Invested in Pathos AI’s Series E Round?

Bristol Myers Squibb led the $237 million Series E financing.

Existing investors also participated in the round, but their individual names and investment amounts were not disclosed in the announcement.

Why the Funding Matters

Pathos AI plans to use the funding to expand Foundry's capabilities and accelerate clinical development across its drug portfolio.

Additional funding will support the clinical development of AZD4241, an oestrogen receptor PROTAC partnered with AstraZeneca, and DO-2, a next-generation MET kinase inhibitor.

These investments will support the company's use of AI-driven analysis to guide clinical development decisions and advance its oncology treatments.

"We are building a platform to systematically improve the probability of success in drug development,” said Iker Huerga, CEO of Pathos. "Foundry has fundamentally accelerated our ability to identify highly promising clinical assets and integrate them into our pipeline.

Market and Business Growth

Pathos AI has expanded its clinical-stage oncology pipeline to four active clinical assets through a series of strategic transactions.

Its programmes target several cancer areas, including metastatic castration-resistant prostate cancer, multiple myeloma, MET-altered non-small-cell lung cancer, ER-positive/HER2-negative breast cancer, and solid tumours expressing TROP2 and HER3.

The latest financing values Pathos AI at approximately $3 billion. The company has not disclosed revenue figures or other commercial performance metrics in the announcement.

What Happens Next?

Pathos AI plans to expand its Foundry platform and accelerate clinical development across its oncology pipeline.

The company will prioritise advancing JSKN016 towards registrational studies while progressing pocenbrodib, AZD4241, and DO-2 through their respective clinical development programmes.

Read More:AEG Presents Appoints Chris Hammond as Senior Vice President